Bevacizumab/steroids/thalidomideLack of efficacy and off label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1933卷 / 1期

关键词：

D O I：

10.1007/s40278-022-28071-4

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：120 / 120

相关论文

共 50 条

[1] Retinoids/steroids/thalidomideLack of efficacy: case report
Reactions Weekly, 2024, 2027 (1) : 443 - 443
[2] Bevacizumab/sirolimusLack of efficacy and off-label use: case report
Reactions Weekly, 2022, 1913 (1) : 118 - 118
[3] Antidiarrhoeals/Bevacizumab/SteroidsLack of efficacy and off-label use: case report
Reactions Weekly, 2025, 2040 (1) : 77 - 77
[4] Remdesivir/steroids/tocilizumabLack of efficacy and off-label use: case report
Reactions Weekly, 2022, 1917 (1) : 505 - 505
[5] Cyclophosphamide/Prednisone/ThalidomideLack of efficacy following off-label use
Reactions Weekly, 2024, 2016 (1) : 156 - 156
[6] ThalidomideLack of efficacy: case report
Reactions Weekly, 2021, 1865 (1) : 394 - 394
[7] Bevacizumab/povidone-iodineEndophthalmitis following off-label use of bevacizumab and lack of efficacy: case report
Reactions Weekly, 2025, 2046 (1) : 79 - 79
[8] ThalidomideLack of efficacy: case report
Reactions Weekly, 2021, 1885 (1) : 480 - 480
[9] ThalidomideLack of efficacy: case report
Reactions Weekly, 2021, 1848 (1) : 365 - 365
[10] AntihypertensivesLack of efficacy and off label use : case report
Reactions Weekly, 2021, 1871 (1) : 47 - 47

← 1 2 3 4 5 →